Update on highly active antiretroviral therapy: Progress and strategies

Biomedicine and Pharmacotherapy

Volumn 54, Issue 1, 2000, Pages 7-12

  Clumeck, N ^a   De Wit, S ^a  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Antiretroviral therapy; Immunologic approach; Salvage therapy; Strategies

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; IMMUNOMODULATING AGENT; INTEGRASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

GENE THERAPY; GENOTYPE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE DEFICIENCY; LYMPHOCYTE COUNT; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SALVAGE THERAPY; VIRUS INHIBITION; VIRUS LOAD; VIRUS RESISTANCE;

EID: 0034143429     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(00)88634-5     Document Type: Article

References (25)

1. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Merigan TC, CPCRA 046 Study Team for the Terry Beim Community Programs for Clinical Research on AIDS (CPCRA). A pilot study of the short-term effects of antiretroviral management based on plasma genotypic antiretroviral resistance testing (GART) in patients failing antiretroviral therapy, 6th Conference on Retroviruses and Opportunistic Infection, Chicago, 31 Jan.-4 Feb. 1999.
2. Brinkman K, Smeitink JA, Romijn JA, Reiss P. Mitochondrial toxicity induced by nucleoside-analogue reverse-transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral-therapy-related lipodystrophy. Lancet 1999 ; 354 : 1112-5.
3. Cameron DW, Japour AJ, Xu Y, Hsu A, Mellors J, Farthing C, et al. Ritonavir and Saquinavir combination therapy for the treatment of HIV infection. AIDS 1999 ; 13 : 213-24.
4. Clumeck N. A phase 3b randomised, open-label, multicentre study to evaluate the safety and efficacy of 2 nrti/abacavir versus continued 2 NRTI/PI treatment in HIV-1 infected subjects with undetectable plasma HIV-1 RNA levels (CNA30017). 7th European Conference on Clinical Aspects and Treatment of HIV-infection [abstract 449]. Lisbon, Portugal October 23-27, 1999.
5. Department of Health and Human Services and Henry J. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. NMWR 1998 ; 47 (RR-5) : 43-82.
6. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al. Drug-resistance genotyping in HIV-1 therapy: The VIRADAPT randomised controlled trial. Lancet 1999 ; 353 : 2195-9.
7. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997 ; 337 : 734-9.
8. Havlir DV, Marschner IC, Hirsch MS, Collier AC, Tebas P, Bassett RL, et al. Maintenance antiretroviral therapies in HIV infected patients with undetectable plasma HIV-RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team. N Engl J Med 1998 ; 339 : 1261-8.
9. Hirsch MS, Conway B, D'Aquila RT, Johnson VA, BrunVezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS society-USA panel. JAMA 1998; 279: 1984-91.
10. Katzenstein DA, Hammer SM, Hughes MD, Gundacker H, Jackson JB, Fiscus S, et al. The relation of virologie and immunologie markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med 1996 ; 335 : 1091-8.
11. Kilby JM, Hopkins S, Venetta TM, Di Massimo B, Cloud GA, Lee JY, et al. Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med 1998 ; 4 : 1302-7.
12. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey Jr FT, Walker RE, et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N Engl J Med 1996 ; 335 : 1350-6.
13. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet 1999 ; 353 : 863-8.
14. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologie failure and adverse drug reactions. Ann Intern Med 1999 ; 131 : 81-7.
15. Montaner JSG, Raboud JM, Rae S for the INCAS and AVANTI Study Groups, et al. Adherence to treatment increases duration of virologie suppression regardless of pVL nadir [abstract LB 10]. In: Program and Abstracts of the 38th Interscience Conference on Antimocrobial Agents and Chemotherapy. San Diego, 1998.
16. Murphy RL, Katlama C, Johnson V, Squires K, Horban A, Gatell JM, et al. The Atlantic study: A randomized, open-label trial comparing two protease inhibitor (PI) sparing antiretroviral strategies versus a standard PI containing regimen: 48 week data. Presented at the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 26-29, 1999.
17. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV outpatient study investigators. N Engl J Med 1998; 338: 853-60.
18. Pialoux G, Raffi F, Brun-Vezinet F, Meiffredy V, Flandre P, Gastaut JA, et al. A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients (trilege). N Engl J Med 1998 ; 339 : 1269-76.
19. Rozenbaum W, Delphin N, Katlama C, Massip P, Bentata M, Mamet JP, et al. Treatment intensification with ziagen in HIV infected patients with previous 3TC/ZDV antiretroviral treatment CNAB3009 [abstract 377]. 6th Conference on Retroviruses and Opportunistic Infection, Chicago, 31 Jan.- 4 Feb. 1999.
20. Ruiz L, van Lunzen J, Arno A, Stellbrink HJ, Schneider C, Rull M, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999 ; 13 : F1-F8.
21. Staszewski S, Keiser P, Gathe J, Haas D, Montaner J, Johnson M, et al. Comparison of antiviral response with abacavir/combivir to indinavir/combivir in therapy-naive adults at 48 weeks (CNA3005). Abstract of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Sept 26-29, 1999. Washington, DC: American Society for Microbiology; 1999. p. 472.
22. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, et al. Efavirenz plus zidovudine and lamivudine versus efavirenz plus indinavir versus indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. N Engl J Med 1999 (In press).
23. Vernazza P, Katlama C, Clotet B, Plettenberg A, Goh L, Cutrell A, et al. Intensification of stable background antiretroviral therapy with Ziagen [abstract 378], 6th Conference on Retroviruses and Opportunistic Infection, Chicago, 31 Jan.- 4 Feb. 1999.
24. Zennou V, Mammano F, Paulous S, Marhez D, Clavel F. Loss of viral fitness associated with multiple gag and gag-pol processing effects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. J Virol 1998 ; 72 : 3300-6.
25. Clumeck N. Choosing the best initial therapy for HIV-1 infection [editorial]. N Engl J Med 1999 ; 341 : 1925-6.